@article{aa33738d318c42248bf7058472f96573,
title = "Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy: Journal of Neurology, Neurosurgery and Psychiatry",
abstract = "Objectives To determine the prevalence of different comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and their impact on outcome, treatment choice and response. Methods Using a structured questionnaire, we collected information on comorbidities from 393 patients with CIDP fulfilling the European Federation of Neurological Societies and Peripheral Nerve Society criteria included in the Italian CIDP database. Results One or more comorbidities were reported by 294 patients (75%) and potentially influenced treatment choice in 192 (49%) leading to a less frequent use of corticosteroids. Response to treatment did not differ, however, from that in patients without comorbidities. Diabetes (14%), monoclonal gammopathy of undetermined significance (MGUS) (12%) and other immune disorders (16%) were significantly more frequent in patients with CIDP than expected in the general European population. Patients with diabetes had higher disability scores, worse quality of life and a less frequent treatment response compared with patients without diabetes. Patients with IgG-IgA or IgM MGUS had an older age at CIDP onset while patients with other immune disorders had a younger age at onset and were more frequently females. IgM MGUS was more frequent in patients with motor CIDP than in patients with typical CIDP. Conclusions Comorbidities are frequent in patients with CIDP and in almost 50% of them have an impact on treatment choice. Diabetes, MGUS and other immune diseases are more frequent in patients with CIDP than in the general population. Only diabetes seems, however, to have an impact on disease severity and treatment response possibly reflecting in some patients a coexisting diabetic neuropathy. {\textcopyright}",
keywords = "corticosteroid, immunoglobulin A, immunoglobulin G, adolescent, adult, aged, Article, child, clinical feature, clinical outcome, comorbidity, controlled study, diabetes mellitus, diabetic neuropathy, disease association, disease severity, female, human, major clinical study, male, monoclonal immunoglobulinemia, onset age, physical disability, polyradiculoneuropathy, prevalence, priority journal, quality of life, questionnaire, retrospective study, treatment response",
author = "P.E. Doneddu and D. Cocito and F. Manganelli and R. Fazio and C. Briani and M. Filosto and L. Benedetti and E. Bianchi and S. Jann and A. Mazzeo and G. Antonini and G. Cosentino and G.A. Marfia and A. Cortese and A.M. Clerici and M. Carpo and A. Schenone and G. Siciliano and M. Luigetti and G. Lauria and T. Rosso and G. Cavaletti and E. Beghi and G. Liberatore and L. Santoro and E. Spina and E. Peci and S. Tronci and M. Ruiz and {Cotti Piccinelli}, S. and E.P. Verrengia and L. Gentile and L. Leonardi and G. Mataluni and L. Piccolo and E. Nobile-Orazio",
note = "Cited By :1 Export Date: 11 March 2021 CODEN: JNNPA Correspondence Address: Nobile-Orazio, E.; Department of Medical Biotechnology and Translational Medicine, Italy; email: eduardo.nobile@unimi.it Chemicals/CAS: immunoglobulin G, 97794-27-9 Funding details: RF0180 Funding details: Shire Funding details: CSL Behring Funding details: Regione Lombardia Funding text 1: Funding The study was supported by a Research Grant from Regione Lombardia, Italy, (grant no. n/a; Progetto Ricerca Indipendente 2012–2013 {\textquoteright}Una rete lombarda per lo studio della Poliradicoloneuropatia Cronica Infiammatoria Demielinizzante (CIDP) (RF0180) e delle sue varianti per ottimizzare il processo diagnostico e terapeutico alla luce dei costi e del miglioramento della qualit{\`a} della vita{\textquoteright}); a Research Grant (2015, grant no. n/a;) from the GBS-CIDP Foundation International (USA) ({\textquoteright}An Italian Multicenter Network for the Diagnosis and Therapy of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and of its Variants{\textquoteright}) and by unrestricted grants (grant nos. n/a) on the same subject form Kedrion Biopharma (Italy), CSL Behring (Italy) and Humanitas Clinical and Research Institute (Milan, Italy). Funding text 2: Disclaimer The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing interests PED has received travel grants to attend scientific meetings from CSL Behring and Kedrion. DC has received honoraria for lecturing from Shire, CSL Behring and Kedrion and travel grants to attend scientific meeting from Shire, Kedrion, and CSL Behring. FM reports personal fees for scientific events from CSL Behring and has received travel grants to attend scientific meetings from CSL Behring and Kedrion. RF has served on scientific advisory boards for CSL Behring and has received travel grants from Kedrion and CSL Behring to attend scientific meeting. Chiara Briani has served on scientific advisory boards for Pfizer, Alnylam, and Akcea, and has received travel grants from Kedrion and CSL Behring to attend scientific meeting. MF has served on scientific advisory boards for CSL Behring and has received travel grants from Kedrion, Baxter and CSL Behring to attend scientific meeting. SJ has received research grants from Grifols, outside this work, and travel grants from Grifols and Kedrion. Anna Mazzeo has received travel grants from Kedrion and CSL Behring to attend scientific meeting. GC has received travel grants to attend scientific meetings from CSL Behring and Kedrion. AC has received travel grants to attend scientific meetings from Kedrion. MC has received travel grants to attend scientific meetings from Kedrion. ML has received travel grants to attend scientific meetings from Kedrion. GC has received honoraria for lecturing and travel grants to attend scientific meetings from Kedrion. E Beghi reports grants from UCB-Pharma, grants from Shire, grants from EISAI, personal fees from Viropharma, grants from Italian Ministry of Health, grants from Fondazione Borgonovo, grants from Associazione IDIC 15, grants from European Union, outside the submitted work. Giuseppe Liberatore has received travel grants to attend scientific meetings from CSL Behring and Kedrion. Lucio Santoro reports personal fees for scientific events from CSL Behring and has received travel grants to attend scientific meetings from CSL Behring and Kedrion. EP has received travel grants to attend scientific meetings from CSL Behring. Eduardo Nobile Orazio reports personal fees for Advisory or Scientific Board from Kedrion, Italy, Baxter, Italy, Novartis, Switzerland, CSL-Behring, Italy, Astellas, the Netherlands, outside the submitted work and travel grants to attend Scientific Meeting from Baxter, Grifols, Kedrion, and Novartis, Italy. The other authors declare no conflict of interest.",
year = "2020",
doi = "10.1136/jnnp-2020-323615",
language = "English",
volume = "91",
pages = "1092--1099",
journal = "J. Neurol. Neurosurg. Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "10",
}